Response rate of regiment carboplatin plus etoposide for non-small cell lung cancer is inferior than regiment used new agent as paclitaxel, docetaxel or gemcitabine. On the other hand, the combination response of chemoradiotherapy could efficacy for non-small cell lunf cancer However, there is still controvers about the toxixities if full dosed chemotheapy is used in concurrent chemoradiotherap…
Chemotherapy result at lung cancer patient be minimized by hematology imbalance during therarapy period. Present data show that grade 3 or 4 of hematology toxicities due to chemotherapy with regimen carboplatin + paclitaxel were rare. A cross sectional study have done to evaluhemotherapy weekly the hematology toxicities of carboplatin plus etoposide or paclitaxel as first line therapy in pat…
Chemotherapy result at lung cancer patient often be minimized by hematology imbalance during therapy period. Erythropoientin (EPO) and interleukin IL-3 were important for making red blood cell. White blood cell and platelets cell. This research was done to se whether EPO and IL-3 at lung cancer patient serum could be prediction factor for anemia caused by chemotherapy. The objective of this st…